Key Takeaways
- Semaglutide mimics a natural gut hormone called GLP-1, which is normally released after meals to coordinate digestion, blood sugar, and appetite.
- It activates GLP-1 receptors in the pancreas (more insulin, less glucagon), stomach (slower emptying), and brain (less hunger, earlier fullness).
- The result is lower blood glucose, longer satiety after meals, and reduced caloric intake, which produces gradual weight loss in most patients.
- In the STEP 1 trial (Wilding et al., NEJM 2021), patients on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks vs 2.4% on placebo.
- Semaglutide is FDA-approved as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as the oral version for diabetes.
Direct answer (40-60 words)
Semaglutide mimics the natural gut hormone GLP-1, activating receptors in the pancreas to increase insulin and decrease glucagon, in the stomach to slow gastric emptying, and in the brain to reduce appetite. The combined effect lowers blood sugar and reduces calorie intake, producing an average 14.9% weight loss over 68 weeks at the 2.4 mg dose.
Table of contents
- The 30-second answer
- What semaglutide is (and isn't)
- How GLP-1 normally works in your body
- What semaglutide does, organ by organ
- The cumulative effect on weight and blood sugar
- The clinical trial evidence
- What semaglutide doesn't do
- The difference between Ozempic, Wegovy, and Rybelsus
- Compounded semaglutide vs brand-name
- FAQ
- Sources
What semaglutide is (and isn't)
Semaglutide is a synthetic peptide that mimics a natural human hormone called glucagon-like peptide-1 (GLP-1). GLP-1 is a 30-amino-acid peptide your gut releases after a meal to coordinate the body's response to incoming food. Semaglutide is structurally similar to GLP-1 but modified at three amino-acid positions and connected to a fatty acid chain. These modifications give it a half-life of about 7 days in the bloodstream, compared with 1 to 2 minutes for natural GLP-1.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Semaglutide is not insulin, not a stimulant, not a fat-burner, and not a diuretic. It doesn't directly burn fat. It changes the signals your body uses to regulate hunger, fullness, blood sugar, and digestion. The weight loss that results is a downstream effect of those signal changes, not a direct pharmacological "fat-melting" action.
The drug was approved by the FDA in 2017 (as Ozempic, for type 2 diabetes), 2019 (as Rybelsus, the oral version for diabetes), and 2021 (as Wegovy, for chronic weight management in patients with BMI 30+ or BMI 27+ with weight-related comorbidities).
How GLP-1 normally works in your body
To understand what semaglutide does, you need to know what natural GLP-1 does. When you eat a meal, specialized cells in your small intestine called L-cells sense the arrival of food and release GLP-1 into the bloodstream. GLP-1 then travels to several organs and triggers a coordinated post-meal response.
In the pancreas, GLP-1 tells beta cells to release more insulin (lowering blood sugar) and tells alpha cells to release less glucagon (further lowering blood sugar by reducing liver glucose output). This happens only when blood sugar is elevated, which is why GLP-1 doesn't cause hypoglycemia in people without diabetes.
In the stomach, GLP-1 slows gastric emptying. Food sits longer, which extends satiety and slows the rise in post-meal blood sugar.
In the brain, GLP-1 acts on receptors in the hypothalamus and brainstem to suppress appetite. This is why most people stop eating before they're stuffed: GLP-1 is signaling fullness.
Natural GLP-1 has one big problem for therapeutic use: it gets degraded by an enzyme called DPP-4 within minutes. The body produces it after every meal, and it disappears within minutes. That's how the system is designed to work for normal meal regulation.
Semaglutide is engineered to resist DPP-4 degradation, which is what gives it the 7-day half-life that makes once-weekly dosing possible.
What semaglutide does, organ by organ
Semaglutide binds to and activates GLP-1 receptors throughout the body. Here's the organ-by-organ breakdown.
The pancreas. Semaglutide makes the beta cells more responsive to glucose, releasing insulin when blood sugar rises. It simultaneously suppresses glucagon release from alpha cells. The combined effect is a 1.5 to 2.0 percentage-point reduction in HbA1c over 26 to 52 weeks at the 1.0 mg or 2.0 mg weekly diabetes dose, per the SUSTAIN trial program (Sorli et al., Lancet Diabetes & Endocrinology 2017).
The stomach. Semaglutide slows gastric emptying. Normal gastric emptying half-time is about 90 minutes. On semaglutide it can extend to 2 to 3 hours, especially after fatty meals. This is the mechanism behind both the prolonged fullness many patients describe and the nausea, reflux, and constipation that can occur during titration.
The brain. Semaglutide acts on the arcuate nucleus of the hypothalamus and the area postrema in the brainstem. These are the brain's hunger and satiety control centers. The result is reduced appetite, earlier fullness during meals, and reduced "food noise," the term patients use for constant background thoughts about food. Brain-imaging studies (van Bloemendaal et al., Diabetes 2014) show measurable reductions in food-cue reactivity in reward-related brain regions.
The liver. GLP-1 receptor activation reduces hepatic glucose production and may improve hepatic steatosis (fatty liver). A 2021 phase 2 trial (Newsome et al., NEJM 2021) showed semaglutide produced a higher rate of NASH resolution compared with placebo in patients with non-alcoholic steatohepatitis.
The heart. GLP-1 receptors are present in cardiac tissue. Several large cardiovascular outcomes trials (SUSTAIN-6 in 2016, SELECT in 2023) have shown semaglutide reduces major adverse cardiovascular events in high-risk patients. The SELECT trial (Lincoff et al., NEJM 2023) found a 20% reduction in cardiovascular death, non-fatal heart attack, or non-fatal stroke in patients with established cardiovascular disease and obesity but without diabetes.
The kidney. GLP-1 receptor activation has nephroprotective effects in diabetic kidney disease. The FLOW trial (Perkovic et al., NEJM 2024) showed reduced progression of kidney disease in type 2 diabetes patients on semaglutide.
The cumulative effect on weight and blood sugar
The interesting part isn't any single organ effect. It's how they stack.
A typical patient starts semaglutide. Over the first 4 to 8 weeks of titration, gastric emptying slows. Hunger between meals drops. The brain's reward response to food cues decreases. Insulin secretion improves. Glucagon secretion drops. The patient eats fewer calories per meal because they feel full sooner. They snack less because hunger between meals is muted. They make different food choices because high-fat, high-volume foods feel less rewarding and may even feel uncomfortable.
The cumulative caloric intake reduction is typically 500 to 1,200 calories per day, sustained week after week. That deficit drives the weight loss.
Blood sugar control improves through three independent paths: better insulin response, lower glucagon, and slower glucose absorption from the gut. In type 2 diabetics, that translates to a 1.5 to 2.0 percentage-point HbA1c reduction. In people without diabetes, fasting and post-meal glucose drop modestly but stay in normal ranges.
The combined effect on weight and blood sugar is what makes semaglutide a different category of medication from anything that came before it. It's not just an appetite suppressant or a glucose-lowering drug. It's a coordinated metabolic-signaling intervention.
The clinical trial evidence
The two most-cited weight-loss trials are STEP 1 and STEP 8.
STEP 1 (Wilding JPH et al., NEJM 2021): 1,961 adults with obesity (BMI 30+) or overweight with comorbidities (BMI 27+). 68 weeks of semaglutide 2.4 mg weekly vs placebo. Results: 14.9% body weight loss in the semaglutide group vs 2.4% in placebo. 86.4% of the semaglutide group lost 5% or more, vs 31.5% of placebo. 50.5% lost 15% or more, vs 4.9% of placebo.
STEP 8 (Rubino DM et al., JAMA 2022): semaglutide vs liraglutide head-to-head over 68 weeks. Semaglutide 2.4 mg produced 15.8% body weight loss vs 6.4% on liraglutide 3.0 mg.
For diabetes, the SUSTAIN program produced a series of trials at the 0.5 mg, 1.0 mg, and 2.0 mg weekly doses. HbA1c reductions ranged from 1.4% to 2.1% across trial conditions, with consistent advantage over comparator drugs (insulin glargine, sitagliptin, exenatide).
For cardiovascular outcomes, SELECT (Lincoff AM et al., NEJM 2023) followed 17,604 adults with cardiovascular disease and overweight/obesity but no diabetes for an average of 39.8 months. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% compared with placebo.
For NASH, the phase 2 trial (Newsome PN et al., NEJM 2021) showed 59% NASH resolution at 0.4 mg daily semaglutide vs 17% on placebo, though without significant fibrosis improvement.
For sleep apnea, the SURMOUNT-OSA trial showed reductions in apnea-hypopnea index, though that trial used tirzepatide rather than semaglutide.
What semaglutide doesn't do
Several common assumptions about semaglutide are wrong.
It doesn't burn fat. No drug on the market directly burns fat. Semaglutide reduces calorie intake, and the resulting energy deficit causes the body to mobilize fat stores for energy. The fat loss is downstream of the calorie deficit.
It doesn't increase metabolism. Resting metabolic rate actually decreases modestly during semaglutide-driven weight loss, in line with what's expected from any caloric-deficit weight loss. The drug doesn't have a thermogenic or stimulant effect.
It doesn't permanently change your set point. When semaglutide is discontinued, appetite returns to its previous baseline within weeks to months. Most patients regain a substantial portion of lost weight within 1 to 2 years off the medication unless they've established new habits during the loss phase. The STEP 4 extension trial (Rubino DM et al., JAMA 2021) documented this regain pattern.
It doesn't selectively burn belly fat or any other specific fat depot. Weight loss on semaglutide follows the same pattern as weight loss from any caloric deficit. Visceral and subcutaneous fat both decrease. The percentage breakdown varies by individual but isn't drug-specific.
It doesn't replace exercise or healthy diet. Patients who pair semaglutide with resistance training and adequate protein retain more lean mass and have better long-term outcomes (Mata Ordoñez et al., Nutrients 2021). Without those, lean mass loss is higher and skin and metabolic health outcomes are worse.
It doesn't work the same way as bariatric surgery. Surgery causes mechanical and hormonal changes that produce larger and more durable weight loss for many patients. Semaglutide works through a single hormonal axis. Both are valid options for severe obesity and have different risk-benefit profiles.
The difference between Ozempic, Wegovy, and Rybelsus
All three contain semaglutide. The differences are in formulation, dose, and FDA-approved indication.
| Brand name | Active ingredient | Form | Doses available | FDA-approved indication |
|---|---|---|---|---|
| Ozempic | Semaglutide | Weekly subcutaneous injection | 0.25, 0.5, 1, 2 mg per week | Type 2 diabetes |
| Wegovy | Semaglutide | Weekly subcutaneous injection | 0.25, 0.5, 1, 1.7, 2.4 mg per week | Chronic weight management (BMI 30+ or BMI 27+ with comorbidity) |
| Rybelsus | Semaglutide | Daily oral tablet | 3, 7, 14 mg per day | Type 2 diabetes |
The biological active ingredient is the same molecule in all three. Wegovy goes higher in dose (up to 2.4 mg) than Ozempic (up to 2 mg) because the weight-loss indication uses a higher target dose. Rybelsus uses much higher daily doses to compensate for the much lower oral bioavailability.
When prescribed off-label for weight loss, Ozempic acts the same way Wegovy does at equivalent doses. The choice between brands often comes down to insurance coverage and pharmacy stock.
Compounded semaglutide vs brand-name
Compounded semaglutide is a custom-prepared formulation made by a state-licensed compounding pharmacy in response to an individual prescription. It contains semaglutide as the active ingredient. It's not an FDA-approved drug.
The differences from brand-name semaglutide:
- Manufacturing: brand-name is made under FDA-supervised manufacturing standards (cGMP). Compounded versions are made under state pharmacy board oversight, which is less rigorous than FDA cGMP.
- Approval: brand-name has gone through clinical trials. Compounded has not.
- Concentration: compounded versions are typically supplied in vials at custom concentrations (commonly 5 mg/mL or 10 mg/mL) and drawn with U-100 insulin syringes. Brand-name is supplied in pre-filled pens with fixed doses.
- Cost: compounded is generally cheaper per month, especially for cash-pay patients. Brand-name pricing varies dramatically depending on insurance coverage.
- Additives: some compounded formulations include B12, B6, or other vitamins. These don't change the semaglutide mechanism.
The mechanism of action is the same because the active molecule is the same. The risk profile is also broadly the same, with the caveat that compounded products are not FDA-reviewed for purity, potency, or stability. Decisions about whether to use compounded semaglutide should be made with a licensed clinician.
For a deeper look at the cost difference, see /articles/cost-and-insurance/semaglutide-cost-comparison/.
FAQ
What does semaglutide actually do in your body? Semaglutide activates GLP-1 receptors in the pancreas (more insulin, less glucagon), the stomach (slower emptying), and the brain (less hunger, earlier fullness). The result is lower blood sugar and reduced calorie intake, which produces gradual weight loss.
How quickly does semaglutide start working? Blood-sugar effects start within hours of the first dose. Appetite suppression starts within days but builds over the first 4 to 8 weeks of titration. Weight loss is gradual, with the bulk of loss happening over 6 to 12 months at the maintenance dose.
Is semaglutide safe for non-diabetics? Yes, for patients who meet the FDA-approved BMI criteria for weight management (BMI 30+ or BMI 27+ with a weight-related comorbidity). The SELECT trial demonstrated safety and cardiovascular benefit in non-diabetic patients with cardiovascular disease.
Does semaglutide burn fat directly? No. Semaglutide reduces calorie intake by suppressing appetite and slowing digestion. The resulting energy deficit causes the body to use stored fat for energy. The fat loss is downstream of the calorie deficit, not a direct drug effect.
Why do people stop eating sooner on semaglutide? Semaglutide slows gastric emptying, so food sits in the stomach longer per meal. It also activates brain regions that signal fullness. Combined with reduced hunger between meals, the net effect is smaller meals and fewer snacks.
What's the difference between semaglutide and tirzepatide? Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors. Tirzepatide has produced larger weight-loss results in head-to-head data (around 20% body weight loss at the 15 mg dose vs 14.9% for semaglutide at 2.4 mg).
Does semaglutide affect mood or mental health? Some patients report mood improvements during weight loss, often related to better blood sugar stability and improved physical comfort. A small minority report depressed mood or anxiety. The FDA monitors this signal in postmarket surveillance and current data does not show a causal link to suicidal ideation, though patients should report any mood changes to their provider.
Can I drink alcohol on semaglutide? You can, with caveats. Many patients report dramatically reduced alcohol cravings on semaglutide, which is being studied formally for alcohol use disorder. Alcohol can worsen nausea during titration. Some patients with type 2 diabetes have a slightly higher hypoglycemia risk when drinking on semaglutide.
How long do you stay on semaglutide? For chronic weight management, semaglutide is typically a long-term medication. The STEP 4 trial showed weight regain within months when patients discontinued. For type 2 diabetes, it's also generally long-term, though some patients with substantial weight loss can reduce or discontinue diabetes medications.
Does semaglutide cause hair loss? Hair shedding (telogen effluvium) occurs in roughly 3% of patients in clinical trials, similar to what's seen with any rapid weight loss. It's typically temporary, peaking 3 to 6 months after starting, and usually resolves within 6 to 9 months. Adequate protein intake reduces the risk.
Can semaglutide reverse type 2 diabetes? Some patients achieve diabetes remission (HbA1c under 6.5% off all medications) on semaglutide combined with significant weight loss. This is more common in patients with shorter diabetes duration and better preserved beta-cell function. It's not guaranteed and isn't the same as a cure.
Does semaglutide work without diet and exercise? Semaglutide reduces calorie intake on its own through appetite suppression, so patients lose weight even without intentional dieting. However, results are dramatically better with adequate protein intake, resistance training, and basic dietary structure. Without those, more lean mass is lost and outcomes are worse.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
- Rubino DM, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
- Rubino DM, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight (STEP 8). JAMA. 2022;327(2):138-150.
- Sorli C, et al. Efficacy and safety of once-weekly semaglutide (SUSTAIN-1). Lancet Diabetes & Endocrinology. 2017;5(4):251-260.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232.
- Newsome PN, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New England Journal of Medicine. 2021;384:1113-1124.
- Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine. 2024;391:109-121.
- van Bloemendaal L, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas. Diabetes. 2014;63(12):4186-4196.
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375:1834-1844.
- Mata Ordoñez F, et al. Resistance training preserves lean mass during caloric restriction. Nutrients. 2021;13(11):3895.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.